Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. May 7, 2021; 27(17): 1959-1972
Published online May 7, 2021. doi: 10.3748/wjg.v27.i17.1959
Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond
Mohamed Shengir, Mohamed Elgara, Giada Sebastiani
Mohamed Shengir, Department of Medicine, McGill University, Montreal, Quebec H3A0G4, Canada
Mohamed Elgara, Department of Internal Medicine, Hamad Medical Corporation, Doha 3050, Qatar
Giada Sebastiani, Department of Medicine, McGill University Health Center, Montreal, Quebec H4A3J1, Canada
Author contributions: Shengir M wrote the paper; Elgara M participated in writing the paper; Sebastiani G reviewed and critically revised the manuscript.
Supported by Junior 1 and 2 Salary Award from Fonds de la Recherche en Santé du Québec, No. 27127; Junior 1 and 2 Salary Award from Fonds de la Recherche en Santé du Québec, No. 267806; Research Salary from the Department of Medicine of McGill University; and Pfizer via Unrestricted Educational Grant.
Conflict-of-interest statement: Sebastiani G has acted as speaker for Merck, Gilead, Abbvie, Novonordisk, Novartis, Pfizer, served as an advisory board member for Merck, Intercept, Novartis, Gilead, Allergan, Pfizer and has received research funding from Merck and Theratec Inc. Shengir M has received honoraria from Gilead. Elgara M has nothing to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Giada Sebastiani, MD, Associate Professor, Department of Medicine, McGill University Health Center, 1001 Blvd. Decarie, Montreal, Quebec H4A3J1, Canada. giada.sebastiani@mcgill.ca
Received: January 25, 2021
Peer-review started: January 25, 2021
First decision: February 27, 2021
Revised: March 6, 2021
Accepted: April 12, 2021
Article in press: April 12, 2021
Published online: May 7, 2021
Processing time: 93 Days and 4.2 Hours
Core Tip

Core Tip: The implementation of direct acting antiviral drugs has dramatically changed the landscape of hepatitis C virus (HCV) treatment, with over 95% of patients achieving sustained virologic response (SVR). Although consistent evidence demonstrated better outcomes for both hepatic and extrahepatic complications after viral clearance, data on cardiometabolic manifestation showed inconsistent results. In this review, we are shading light on the latest findings about cardiometabolic extrahepatic manifestations post-SVR. These updates may guide clinicians engaged in HCV care to integrate in their management post-viral eradication risks and subsequent long-term care.